United Guardian (UG) Net Cash Flow Growth (3y) (2013 - 2026)
Powered by 
Analysis
United Guardian (UG) Net Cash Flow Growth (3y) (2013 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | NCF Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 642.97 Bn | 622.21 Bn | 17.26 Bn | 38.95% |
| 2 | AbbVie | 441.24 Bn | 434.67 Bn | 12.70 Bn | -49.89% |
| 3 | Merck | 364.65 Bn | 357.51 Bn | 12.21 Bn | 33.59% |
| 4 | Novartis Ag | 266.30 Bn | 258.61 Bn | 11.24 Bn | 38.53% |
| 5 | Pfizer | 158.95 Bn | 147.25 Bn | 10.94 Bn | -51.84% |
| 6 | Sanofi | 52.43 Bn | 45.05 Bn | 10.79 Bn | 1.06% |
| 7 | Revolution Medicines | 44.29 Bn | 44.29 Bn | - | - |
| 8 | Incyte | 25.27 Bn | 20.73 Bn | 1.57 Bn | 18.67% |
| 9 | United Therapeutics | 21.44 Bn | 18.78 Bn | 683.80 Mn | 95.24% |
| 10 | United Guardian | 32.67 Mn | 23.07 Mn | 1.55 Mn | -32.08% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -32.08% |
| Mar 31, 2026 | -50.18% |
| Dec 31, 2025 | 5.33% |
| Sep 30, 2025 | -103.60% |
| Jun 30, 2025 | -31.35% |
| Mar 31, 2025 | -213.34% |
| Dec 31, 2024 | -52.17% |
| Sep 30, 2024 | -384.18% |
| Jun 30, 2024 | -13.90% |
| Mar 31, 2024 | -84.92% |
| Dec 31, 2023 | 80.06% |
| Sep 30, 2023 | 35.34% |
| Jun 30, 2023 | 16.43% |
| Mar 31, 2023 | 50.95% |
| Dec 31, 2022 | 34.76% |
| Sep 30, 2022 | -45.77% |
| Jun 30, 2022 | -19.30% |
| Mar 31, 2022 | 27.10% |
| Dec 31, 2021 | 2.85% |
| Sep 30, 2021 | 74.40% |